Chunling Liu

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations

Shun Lü, Xiaorong Dong, Hong Jian et al. · Journal of Clinical Oncology · 2022 · 279 citations · Full text

Medicine, Oncology, Pharmacology +16

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

Ying Cheng, Yong He, Wěi Li et al. · Targeted Oncology · 2021 · 162 citations · Full text

Medicine, Oncology, Pharmacology +17

Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study

Yuankai Shi, Xingsheng Hu, Shucai Zhang et al. · The Lancet Respiratory Medicine · 2021 · 121 citations

Medicine, Molecular Genetics, Oncology +17

PET Imaging Study of S1PR1 Expression in a Rat Model of Multiple Sclerosis

Hui Liu, Hongjun Jin, Xuyi Yue et al. · Molecular Imaging and Biology · 2016 · 53 citations · Full text

Life Sciences, Neurology, Neuroscience +12

Zinc transporter SLC39A13/ZIP13 facilitates the metastasis of human ovarian cancer cells via activating Src/FAK signaling pathway

Xinxin Cheng, Jie Wang, Chunling Liu et al. · Journal of Experimental & Clinical Cancer Research · 2021 · 39 citations · Full text

Medicine, Cancer Biology, Oncology +16